Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipopolysaccharide is a complex glycolipid forming the outer leaflet of the outer membrane of Gram-negative bacteria. It consists of three regions: lipid A (membrane anchor and endotoxin activity), core oligosaccharide (structural integrity), and O-antigen polysaccharide (serotype specificity and immune evasion). LPS is essential for bacterial survival, providing a protective barrier against toxic compounds, contributing to biofilm formation, and playing a key role as a pathogen-associated molecular pattern that triggers strong innate immune responses in host organisms. LPS is the principal cause of endotoxin-mediated clinical manifestations during Gram-negative infections, including sepsis and shock. Its diversity and capacity to evade immune responses present major challenges for therapy and diagnosis.
Drugs targeting LPS can disrupt outer membrane integrity, leading to increased permeability and bacterial death (e.g., colistin binds to lipid A, destabilizing the membrane). Blocking LPS recognition by host immune receptors (CD14/TLR4/MD2 complex), reducing proinflammatory cytokine release.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipopolysaccharide in the outer membrane of Gram-negative bacteria (LPS).